Christine K Harris1, Hanh Tam Tran2, Katherine Lee3, Charles Mylander4,5, Daina Pack3, Martin Rosman4, Lorraine Tafra3, Christopher B Umbricht6, Reema Andrade3, Wen Liang3, Rubie Sue Jackson3. 1. Rebecca Fortney Breast Center, Anne Arundel Medical Center, Annapolis, USA. ckzoon@gmail.com. 2. Department of General Surgery, Union Memorial Hospital, Baltimore, USA. 3. Rebecca Fortney Breast Center, Anne Arundel Medical Center, Annapolis, USA. 4. Anne Arundel Medical Center, Annapolis, USA. 5. Division of Mathematics, US Naval Academy, Annapolis, USA. 6. Division of Endocrine and Oncologic Surgery, Johns Hopkins Hospital and Health System, Baltimore, USA.
Abstract
BACKGROUND: The ACOSOG Z0011 (Z11) trial demonstrated that in patients with nonpalpable axillary lymph nodes (LN) and one to two positive sentinel LN (SLN), axillary LN dissection (ALND) is unnecessary.JAMA 305:569-575, [2011], Ann Surg 264:413-42, [2016] The Z11 trial did not require preoperative axillary ultrasound (axUS). In many centers, preoperative axUS is part of the standard workup of a newly diagnosed breast cancer patient, but in light of the Z11 results, its role is now questioned. METHODS: We retrospectively analyzed newly diagnosed breast cancer patients at two institutions. Inclusion criteria were patients with (1) no palpable lymphadenopathy, (2) abnormal axUS, (3) axillary LN metastasis confirmed preoperatively by axUS-lymph node needle biopsy, (4) no neoadjuvant therapy, and (5) ALND. LN disease burden was dichotomized as N1 versus N2-3. We examined relationships between clinicopathologic factors, including axUS characteristics, and LN disease burden. RESULTS: Of 129 included cases, 67 had N1 disease (51.9%) and 62 had N2-3 disease (48.1%). Factors significantly associated with N1 disease were tumor size ≤2 cm (p = 0.012), nonlobular histology (p = 0.013), and one suspicious LN on axUS (p = 0.008). For patients with both tumor size on imaging ≤2 cm and one abnormal LN on axUS, only 27% had N2-3 disease (p = 0.007). CONCLUSIONS: More than half of patients without palpable adenopathy but with preoperative US-guided biopsy proven axillary LN metastases had N1 disease. For patients with both tumor size ≤2 cm and only 1 abnormal LN on axUS, 73% had N1 disease. This suggests that such patients, if they are otherwise analogous to Z11 patients, may undergo attempt at SLNB.
BACKGROUND: The ACOSOG Z0011 (Z11) trial demonstrated that in patients with nonpalpable axillary lymph nodes (LN) and one to two positive sentinel LN (SLN), axillary LN dissection (ALND) is unnecessary.JAMA 305:569-575, [2011], Ann Surg 264:413-42, [2016] The Z11 trial did not require preoperative axillary ultrasound (axUS). In many centers, preoperative axUS is part of the standard workup of a newly diagnosed breast cancerpatient, but in light of the Z11 results, its role is now questioned. METHODS: We retrospectively analyzed newly diagnosed breast cancerpatients at two institutions. Inclusion criteria were patients with (1) no palpable lymphadenopathy, (2) abnormal axUS, (3) axillary LN metastasis confirmed preoperatively by axUS-lymph node needle biopsy, (4) no neoadjuvant therapy, and (5) ALND. LN disease burden was dichotomized as N1 versus N2-3. We examined relationships between clinicopathologic factors, including axUS characteristics, and LN disease burden. RESULTS: Of 129 included cases, 67 had N1 disease (51.9%) and 62 had N2-3 disease (48.1%). Factors significantly associated with N1 disease were tumor size ≤2 cm (p = 0.012), nonlobular histology (p = 0.013), and one suspicious LN on axUS (p = 0.008). For patients with both tumor size on imaging ≤2 cm and one abnormal LN on axUS, only 27% had N2-3 disease (p = 0.007). CONCLUSIONS: More than half of patients without palpable adenopathy but with preoperative US-guided biopsy proven axillary LN metastases had N1 disease. For patients with both tumor size ≤2 cm and only 1 abnormal LN on axUS, 73% had N1 disease. This suggests that such patients, if they are otherwise analogous to Z11 patients, may undergo attempt at SLNB.
Authors: Su Min Ha; Jung Min Chang; Soo-Yeon Kim; Su Hyun Lee; Eun Sil Kim; Yeon Soo Kim; Nariya Cho; Woo Kyung Moon Journal: Breast Cancer Res Treat Date: 2021-01-03 Impact factor: 4.872
Authors: Anna Weiss; Claire King; Julie Vincuilla; Tonia Parker; Leah Portnow; Faina Nakhlis; Laura Dominici; Elizabeth A Mittendorf; Tari A King Journal: Breast Cancer Res Treat Date: 2022-07-28 Impact factor: 4.624
Authors: Eduardo Camargo Millen; Francisco Pimentel Cavalcante; Felipe Zerwes; Guilherme Novita; Alessandra Borba Anton de Souza; João Henrique Penna Reis; Helio Rubens de Oliveira Filho; Luciana Naíra de B L Limongi; Barbara Pace Silva de Assis Carvalho; Adriana Magalhães de Oliveira Freitas; Monica Travassos Jourdan; Vilmar Marques de Oliveira; Ruffo Freitas-Junior Journal: Ann Surg Oncol Date: 2021-09-27 Impact factor: 5.344
Authors: Julia Caroline Radosa; Erich-Franz Solomayer; Martin Deeken; Peter Minko; Julia Sarah Maria Zimmermann; Askin Canguel Kaya; Marc Philipp Radosa; Lisa Stotz; Sarah Huwer; Carolin Müller; Maria Margarete Karsten; Gudrun Wagenpfeil; Christoph Georg Radosa Journal: Ann Surg Oncol Date: 2022-04-29 Impact factor: 4.339
Authors: Su Min Ha; Eun Young Chae; Joo Hee Cha; Hee Jung Shin; Woo Jung Choi; Hak Hee Kim Journal: BMC Med Imaging Date: 2020-05-01 Impact factor: 1.930
Authors: Bello Inua; Victoria Fung; Nour Al-Shurbasi; Sarah Howells; Olga Hatsiopoulou; Praveen Somarajan; Gregory J Zardin; Norman R Williams; Stan Kohlhardt Journal: Mol Clin Oncol Date: 2021-01-21